Apple Approves Use of Avalon GloboCare’s KetoAir Mobile Application
KetoAir™ Mobile Application Launches in Apple App Store
KetoAir™ Mobile Application also Available in the Google Play Store
FREEHOLD, N.J., Oct. 04, 2023 (GLOBE NEWSWIRE) -- Avalon GloboCare Corp. (“Avalon” or the “Company”) (NASDAQ: ALBT), a developer of innovative precision diagnostics and provider of clinical laboratory services, today announced the launch of the KetoAir™ mobile application in the Apple App store. The KetoAir™ mobile application is also available in the Google Play store.
In April 2023, Avalon announced that it has partnered with Qi Diagnostics to exclusively distribute the KetoAir™ in North America, South America, the U.K. and the EU. KetoAir™ functions as a companion diagnostic and monitoring device, combined with an artificial intelligence (AI) nutritionist consultation for ketogenic dietary management (United States FDA registration number: 3026284320).
“We are excited to launch the KetoAir app on the Apple App store. KetoAir™ is the first breathalyzer on the market that uses an AI nutritionist bundled with a nanosensor-based breathalyzer for ketogenic health management. Apple owners can now easily download the app from the Apple App store, pair your KetoAir™ Breathalyzer device via Bluetooth, and log in to track your ketosis record,” commented David Jin, M.D., Ph.D., President and Chief Executive Officer of Avalon. “The KetoAir™ breathalyzer device is the perfect tool for health and wellness conscious individuals who are looking to optimize their ketosis state and body fat burning rate. The pocket-sized breathalyzer provides accurate and instant results in a single blow, giving the user the ability to monitor how different foods and activities affect their ketone level. Additionally, the AI nutritionist on the app will analyze the dietary plan and acts as a companion consultant by providing personalized nutritional and exercise recommendations to help achieve the user’s ultimate health goal.”
About Avalon GloboCare Corp.
Avalon GloboCare Corp. (NASDAQ: ALBT) is a commercial stage company dedicated to developing and delivering innovative, transformative, precision diagnostics and clinical laboratory services. Avalon is establishing a leading role in the innovation of diagnostic testing, utilizing proprietary technology to deliver precise, genetics-driven results. The Company also provides laboratory services, offering a broad portfolio of diagnostic tests including drug testing, toxicology, and a broad array of test services, from general bloodwork to anatomic pathology, and urine toxicology. For more information about Avalon GloboCare, please visit www.avalon-globocare.com.
For the latest updates on Avalon GloboCare’s developments, please follow our twitter at @avalongc_avco.
Forward-Looking Statements
Certain statements contained in this press release may constitute “forward-looking statements.” Forward-looking statements provide current expectations of future events based on certain assumptions and include any statement that does not directly relate to any historical or current fact, including statements regarding LSM. Actual results may differ materially from those indicated by such forward-looking statements as a result of various important factors as disclosed in our filings with the Securities and Exchange Commission located at their website (http://www.sec.gov). In addition to these factors, actual future performance, outcomes, and results may differ materially because of more general factors including (without limitation) general industry and market conditions and growth rates, economic conditions, and governmental and public policy changes. The forward-looking statements included in this press release represent the Company's views as of the date of this press release and these views could change. However, while the Company may elect to update these forward-looking statements at some point in the future, the Company specifically disclaims any obligation to do so. These forward-looking statements should not be relied upon as representing the Company's views as of any date subsequent to the date of the press release.
Contact Information:
Avalon GloboCare Corp.
4400 Route 9, Suite 3100
Freehold, NJ 07728
PR@Avalon-GloboCare.com
Investor Relations:
Crescendo Communications, LLC
Tel: (212) 671-1020 Ext. 304
albt@crescendo-ir.com
Released October 4, 2023